The European Laboratory Research & Innovation Group (ELRIG) UK today announced the keynote speakers for Drug Discovery 2023, going down on the ACC in Liverpool from 18–19 October. Prof Janet Hemingway CBE, FRS, Founding Director of Infection Innovation Consortium (iiCON), and Dr Dave Powell, Chief Scientific Officer (CSO) of LifeArc will lead this 12 months’s event focussing on diverse pondering and recent perspectives.
Sanj Kumar, CEO, ELRIG UK. Image Credit: ELRIG UK
The organization’s free-to-attend, flagship conference will cover a wide selection of themes from ‘omics, and personalized medicine to chemistry; all focused on bringing recent therapies from the lab to the patient.
Janet Hemingway is Professor of Tropical Medicine on the Liverpool School of Tropical Medicine (LSTM) and the Founding Director of iiCON, a collaborative £230 million programme bringing together academic, industry and clinical partners to assist transform the invention and provide of anti-infectives and speed up their journey to market. She is a senior technical advisor on Neglected Tropical Diseases for the Bill and Melinda Gates Foundation and has been PI on projects in excess of £370 million. Prof Hemingway was Director of LSTM from 2001 to 2019 and he or she was awarded a CBE for services to the Control of Tropical Disease Vectors in 2012.
Dave Powell joined LifeArc as CSO in 2022 as the subsequent step in his 25 years in R&D. Prior to this he led the preclinical drug discovery and the phase lll antibiotic research programme at Summit Therapeutics. Dr Powell began his life sciences profession at SmithKline Beecham (now GSK), gaining deep platform and project experience across quite a few therapeutic areas, including neurosciences, oncology, and infectious disease. He also helped to begin after which led the collaboration between GSK and the Francis Crick Institute in London.
Drug Discovery 2023 will include presentations from leaders of their fields, a trade show and exhibition, a poster competition, tech theatres focussed on robotics and automation, and sustainability practices, a bunch of networking opportunities and a learning zone for early profession professionals.
The conference will run 4 parallel sessions every day focussed on: cellular technologies for drug discovery, transforming cancer drug discovery through diverse pondering and innovations, delving into the variety of chemistry, driving molecules from concept to clinic, augmenting R&D with AI, biopharmaceutical discovery, translating ideas into therapies, hit identification and screening, and chemistry enabling drug discovery from begin to clinic.
ELRIG is devoted to delivering great scientific content with diversity and inclusivity in-built, and the calibre of talks at this 12 months’s event are testament to that. The keynote speakers are such influential and highly respected scientists of their respective fields. We’re delighted to have them lead the scientific programme at Drug Discovery 2023 and support us in driving collaboration across the scientific community as we proceed to grow our diverse network.”
Sanj Kumar, CEO, ELRIG UK.
It’s an honour to be presenting at this 12 months’s Drug Discovery event in Liverpool. I look ahead to connecting with thought leaders, sharing insights, and gaining recent perspectives on key areas of importance in the sphere and future directions for novel therapeutics.”
Prof Janet Hemingway, Founding Director, iiCON.
I’m keen about discovery innovation but in addition about how we are able to train and prepare the subsequent generation of drug discovery scientists. So, I’m proud to be presenting at ELRIG’s flagship event this 12 months where recent ideas and technology are at all times to the fore, but importantly ELRIG Drug Discovery is a highly approachable conference for our younger colleagues as well.”
Dr Dave Powell, CSO, LifeArc.
For a full listing of speakers and sessions, to register or book an exhibition stand, please visit: https://www.elrig.org/portfolio/drug-discovery-2023/
Source:
European Laboratory Research & Innovation Group (ELRIG)